Management recommendations for kidney transplantation in patients with plasma cell dyscrasia
Naoka Murakami(Brigham and Women's Hospital), Heather Landau(Memorial Sloan Kettering Cancer Center), Vaishali Sanchorawala(Boston Medical Center), Allison B. Webber(University of California, San Francisco), Sabine Karam(American University of Beirut), Ben Sprangers(KU Leuven), Malin Hultcrantz(United States Fish and Wildlife Service), Ajay Kumar Thakur(The Ohio State University), Naresh Bumma(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Erica Campagnaro(University of Michigan), Raviprasenna Parasuraman(University of Michigan), Miklos Z. Molnar(University of Tennessee Health Science Center), Bhavna Bhasin(Medical College of Wisconsin), Diala Khirfan(Tulane University), Brian Benes(Nebraska Medical Center), Christopher D. Blosser(University of Washington), Anuja Java(Washington University in St. Louis), Erik L. Lum(University of California, Los Angeles), Frank Bridoux(Université de Poitiers), Gaurav Gupta(Gyan Vihar University), Samip Master(Willis-Knighton Cancer Center), Neeraj Singh(Willis-Knighton Cancer Center), Priya Alexander(Mayo Clinic)
Cited by 7
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
|American Journal of Hematology|2005|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
|Annals of Internal Medicine|2004|615